Who owns the IP
The organizations most actively patenting around this compound, ranked by referenced patent volume.
| # | Assignee | Patents |
|---|---|---|
| 1 | Bristol Myers Squibb Co | 174 |
| 2 | Sigma Tau Industrie Farmaceutiche Riunite SpA | 30 |
| 3 | University of Tennessee Research Foundation | 30 |
| 4 | Bioveris Corp | 25 |
| 5 | Oncternal Therapeutics Inc | 20 |
| 6 | Aeterna Zentaris GmbH | 16 |
| 7 | Centre National de la Recherche Scientifique | 16 |
| 8 | Pfizer Corp SRL | 16 |
| 9 | Pfizer Inc | 16 |
| 10 | Merck Sharp & Dohme LLC | 15 |
Explore the full landscape
This preview shows the leading assignees. Cypris reveals the full ownership landscape - every filing entity, filing trends, and portfolio momentum.
Visit CyprisWhere innovation is concentrated
Patent classifications ranked by volume reveal the technical domains with the most active filing.
| # | Code | Area | Patents |
|---|---|---|---|
| 1 | A61P | Therapeutic activity (drug indications) | 533 |
| 2 | C07D | Heterocyclic compounds | 434 |
| 3 | A61K | Medicinal preparations | 320 |
| 4 | C07C | Acyclic and carbocyclic compounds | 108 |
| 5 | G01N | Investigating / analysing materials | 67 |
| 6 | C07F | Organometallic compounds | 50 |
| 7 | C12Q | Measuring/testing involving enzymes | 46 |
| 8 | C07J | 45 | |
| 9 | C07H | Sugars and derivatives | 41 |
| 10 | C07K | Peptides | 38 |
AI mapped opportunity space
This preview shows where patent activity concentrates. Cypris maps the full classification landscape to surface technical whitespace and IP headroom.
See Cypris in actionMost-cited patents
Patents ranked by forward citations reveal the foundational inventions the field continues to build on.
| Title | Year | Assignee | Cited by |
|---|---|---|---|
| Heterogeneous immunoassay for digoxin using ouabain as a separation means | 1985 | Dade Behring Inc | 41 |
| ASSAY METHODS INVOLVING OUABAIN | 1992 | University of Maryland, Baltimore | 39 |
| Antibody having binding specificity for human ouabain | 1998 | University of Maryland, Baltimore | 36 |
| Immunoassay for detecting human ouabain | 1995 | UNIVERSITY OF MARYLAND AT BALTIMORE | 12 |
| Ouabain triacetate derivative compounds | 1991 | Abbott Laboratories | 4 |
Where research is gaining momentum
Research themes ranked by publication activity show where scientific interest is accelerating around this compound.
| # | Research topic | Papers |
|---|---|---|
| 1 | Ion Transport and Channel Regulation | 74 |
| 2 | Ion channel regulation and function | 23 |
| 3 | Cardiac electrophysiology and arrhythmias | 20 |
| 4 | Neuroscience and Neuropharmacology Research | 20 |
| 5 | Nitric Oxide and Endothelin Effects | 10 |
| 6 | Pancreatic function and diabetes | 10 |
| 7 | Erythrocyte Function and Pathophysiology | 9 |
| 8 | Amino Acid Enzymes and Metabolism | 8 |
| 9 | Physiological and biochemical adaptations | 8 |
| 10 | Metabolism and Genetic Disorders | 7 |
Technology trend analysis
Cypris uses AI to connect emerging research themes to IP activity, commercialization signals, and underexplored opportunity areas.
See Cypris in actionWho's driving the science
The most-published authors working with this compound, alongside their primary affiliations.
| # | Author | Affiliation | Papers |
|---|---|---|---|
| 1 | Tai Akera | Michigan State University | 67 |
| 2 | Arnold Schwartz | Baylor College of Medicine | 63 |
| 3 | John M. Hamlyn | University of Maryland, Baltimore | 48 |
| 4 | Erland Erdmann | LMU Klinikum | 45 |
| 5 | Torben Clausen | Aarhus University | 40 |
| 6 | Amir Askari | University of Toledo Medical Center | 35 |
| 7 | David Lichtstein | Hebrew University of Jerusalem | 35 |
| 8 | Frans H. H. Leenen | University of Ottawa | 34 |
| 9 | Jerry B. Lingrel | University of Cincinnati Medical Center | 31 |
| 10 | E. Edward Bittar | University of Wisconsin–Madison | 30 |
Research leaders
This preview lists the top authors. Cypris surfaces the full researcher landscape, their affiliations, and how scientific influence is shifting.
See Cypris in actionThe literature that defines it
The most-cited papers anchoring the scientific record for this compound.
| Title | Year | Cited by | Topic |
|---|---|---|---|
| Two components of cardiac delayed rectifier K+ current. Differential sensitivity to block by class III antiarrhythmic agents. | 1990 | 1472 | Neuroscience and Neuropharmacology Research |
| Haploinsufficiency of ATP1A2 encoding the Na+/K+ pump α2 subunit associated with familial hemiplegic migraine type 2 | 2003 | 945 | Migraine and Headache Studies |
| Purification and characterization of (Na+ + K+)-ATPase III. Purification from the outer medulla of mammalian kidney after selective removal of membrane components by sodium dodecylsulphate | 1974 | 944 | Drug Transport and Resistance Mechanisms |
| Controlling Cardiac Chaos | 1992 | 926 | Chaos control and synchronization |
| Identification and characterization of a ouabain-like compound from human plasma. | 1991 | 783 | Ion Transport and Channel Regulation |
Frequently asked questions
Common questions about this compound's patent and research landscape, answered from the underlying data.
What is the molecular formula and weight of ouabain?
Which organizations hold the most patents related to ouabain?
What are the primary research topics associated with ouabain in the scientific literature?
Who are the leading researchers publishing on ouabain?
What are the primary patent classification areas for ouabain-related inventions?